Likely EU rejection of Biogen's Alzheimer's drug comes as no surprise, says dementia researcher
The negative opinion from a trend vote from the EMA's expert committee, the CHMP, was to be expected, says director of clinical trial unit at the Danish Dementia Research Center. The FDA, not the EMA, has been the outlier in common approval practices.
BY ALBERT RØNNING-ANDERSSON, TRANSLATED BY DANIEL PEDERSEN
It is in the cards, and thus should come as no big surprise, that the pharmaceutical company Biogen is very likely to receive the European thumbs-down for its Alzheimer's drug, Aduhelm (aducanumab).